Last reviewed · How we verify
Interferon beta type 1a
Interferon beta-1a binds to type I interferon receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune cell infiltration into the central nervous system.
Interferon beta-1a binds to type I interferon receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune cell infiltration into the central nervous system. Used for Relapsing-remitting multiple sclerosis, Clinically isolated syndrome with MRI features consistent with multiple sclerosis.
At a glance
| Generic name | Interferon beta type 1a |
|---|---|
| Also known as | Avonex |
| Sponsor | Biogen |
| Drug class | Interferon |
| Target | Type I interferon receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon beta-1a is a recombinant cytokine that activates type I interferon signaling pathways, leading to upregulation of anti-inflammatory genes and downregulation of pro-inflammatory cytokines. It reduces the migration of immune cells across the blood-brain barrier and decreases the activation of autoreactive T cells, thereby reducing demyelinating lesions and disease progression in multiple sclerosis.
Approved indications
- Relapsing-remitting multiple sclerosis
- Clinically isolated syndrome with MRI features consistent with multiple sclerosis
Common side effects
- Injection site reactions
- Flu-like symptoms (fever, chills, myalgia)
- Headache
- Fatigue
- Depression
- Elevated liver enzymes
- Leukopenia
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (PHASE3)
- National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis (PHASE3)
- Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis (PHASE2, PHASE3)
- A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza (PHASE2)
- Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis (PHASE4)
- Public Health Emergency: SOLIDARITY TRIAL Philippines (NA)
- Study of Evobrutinib in Participants With RMS (PHASE3)
- Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon beta type 1a CI brief — competitive landscape report
- Interferon beta type 1a updates RSS · CI watch RSS
- Biogen portfolio CI